73976
document
Protective effect of high-dose medroxyprogesterone acetate ( HD-MPA ) on hematological toxicity induced by chemotherapy for advanced solid tumors : a multicentric controlled clinical trial . MPA-Hematology Italian Cooperative Group . A multicenter , randomized , controlled trial was conducted comparing active treatment with placebo in 227 patients with breast , colorectal , lung and other solid forms of cancer . Combination therapy , ( CT ) conventionally employed for the various types of tumor involved , was associated with MPA ( 117 patients ) or placebo ( 110 patients ) . MPA was given orally as tablets , as a dose of 500 mg b.i.d . for 6 months . The results were , briefly , as follows : The incidence of leukopenia was significantly lower in the groups receiving MPA in patients with breast and colorectal cancer ( P less than 0.02 ) . Tumors of the lung and other solid forms showed no such difference . The incidence of thrombocytopenia was the same in all disease groups . Objective responses ( CR + PR ) were observed in 23/46 ( 50 % ) of breast cancer patients treated with CT + MPA , and in 13/47 ( 28 % ) of those given CT + placebo . The difference was significant ( P less than 0.02 ) . Subjective parameters also showed more improvement in the MPA group than in the patients given CT alone . No significant differences were found for the other types of tumor , but the numbers in this population were very limited . In a group of 45 patients , antithrombin III a ( % ) , antithrombin III R : Ag ( % ) , plasminogen ( mg/dl ) , alpha-2 macroglobulin ( % ) , factor VIII C ( % ) , factor VIII R : Ag ( % ) and factor IX C ( % ) were determined . The most interesting post-treatment findings were an increase in anti-thrombin III ( activity and antigen level ) and in plasminogen . This suggests that MPA does not increase the risk of thrombosis , and might even , to some extent , impede tumor-induced thrombophilia . ( ABSTRACT TRUNCATED AT 250 WORDS )
73977
Intervention_Pharmacological
high-dose medroxyprogesterone acetate ( HD-MPA )
73978
Intervention_Physical
chemotherapy
73979
Intervention_Control
placebo
73980
Intervention_Physical
Combination therapy , ( CT )
73981
Intervention_Pharmacological
MPA
73982
Intervention_Control
placebo
73983
Intervention_Pharmacological
MPA
73984
Intervention_Physical
CT + MPA
73985
Intervention_Control
CT + placebo
73986
Intervention_Physical
MPA
73987
Outcome_Physical
hematological toxicity
73988
Outcome_Physical
incidence of leukopenia
73989
Outcome_Physical
Tumors of the lung and other solid forms
73990
Outcome_Physical
incidence of thrombocytopenia
73991
Outcome_Physical
Objective responses ( CR + PR )
73992
Outcome_Other
Subjective parameters
73993
Outcome_Physical
antithrombin III a ( % ) , antithrombin III R : Ag ( % ) , plasminogen ( mg/dl ) , alpha-2 macroglobulin ( % ) , factor VIII C ( % ) , factor VIII R : Ag ( % ) and factor IX C ( % )
73994
Outcome_Physical
anti-thrombin III ( activity and antigen level ) and in plasminogen